Posts Tagged ‘nasal’
Published paper: Nasodine is an effective treatment for the common cold
Today, we announced that the results of the the first Phase 3 clinical trial of Nasodine Nasal Spray (Nasodine) as a treatment for the common cold (conducted in 2019) have been published in Frontiers in Medicine, a prestigious, high-impact journal. The paper is titled: “Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomised, controlled,…
Nasodine European Marketing Application filed and passed validation
Firebrick Pharma (ASX:FRE) is pleased to announce that it has filed a Marketing Authorisation Application (“MAA”) in Europe for the approval of Nasodine® Nasal Spray as a nasal antiseptic. The MAA has successfully passed validation and has now entered the evaluation phase. The application was filed via a decentralised procedure, where one EU member state,…
New agreement allows Nasodine launch in Philippines
Firebrick Pharma is pleased to announce that it has executed an amended agreement with its existing marketing partner in the Philippines, S.V. More Pharma Corporation (SV More). Under the amended agreement, SV More will have the right to manufacture Nasodine® Nasal Spray (“Nasodine”) in the Philippines, rather than import the product from Australia. This will…
Nasodine Phase 3 common cold trial underway
Firebrick Pharma is pleased to announce that the first patient has been recruited into its confirmatory Phase 3 trial for Nasodine® Nasal Spray (“Nasodine”) as a treatment for the common cold. The randomised controlled Phase 3 trial expects to recruit up to 450 adult subjects with early cold symptoms to achieve a target treatment population…